D
Atea Pharmaceuticals, Inc.
AVIR
$3.06
-$0.04-1.29%
D
Sell
3/7/2025Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 3/7/2025 due to an increase in the volatility index and solvency index. The quick ratio increased from 19.17 to 24.44.
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 3/7/2025 due to an increase in the volatility index and solvency index. The quick ratio increased from 19.17 to 24.44.
E
Sell
3/6/2025Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 3/6/2025 due to a decline in the total return index and volatility index.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 3/6/2025 due to a decline in the total return index and volatility index.
D
Sell
11/8/2024Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 11/8/2024 due to an increase in the growth index and volatility index. Operating cash flow increased 45.42% from -$42.2M to -$23.04M, earnings per share increased from -$0.481 to -$0.369, and EBIT increased 12.6% from -$35.43M to -$30.97M.
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 11/8/2024 due to an increase in the growth index and volatility index. Operating cash flow increased 45.42% from -$42.2M to -$23.04M, earnings per share increased from -$0.481 to -$0.369, and EBIT increased 12.6% from -$35.43M to -$30.97M.
E
Sell
10/24/2024Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 10/24/2024 due to a decline in the volatility index.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 10/24/2024 due to a decline in the volatility index.
D
Sell
10/9/2024Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 10/9/2024 due to an increase in the volatility index.
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 10/9/2024 due to an increase in the volatility index.
E
Sell
9/19/2024Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 9/19/2024 due to a decline in the volatility index.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 9/19/2024 due to a decline in the volatility index.
D
Sell
8/30/2024Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 8/30/2024 due to an increase in the volatility index and total return index.
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 8/30/2024 due to an increase in the volatility index and total return index.
E
Sell
8/15/2024Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 8/15/2024 due to a decline in the volatility index and solvency index.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 8/15/2024 due to a decline in the volatility index and solvency index.
D
Sell
8/2/2024Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 8/2/2024 due to an increase in the total return index and volatility index.
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 8/2/2024 due to an increase in the total return index and volatility index.
E
Sell
7/15/2024Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 7/15/2024 due to a decline in the total return index and volatility index.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 7/15/2024 due to a decline in the total return index and volatility index.
D
Sell
6/26/2024Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 6/26/2024 due to an increase in the volatility index.
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 6/26/2024 due to an increase in the volatility index.
E
Sell
6/10/2024Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 6/10/2024 due to a decline in the growth index, volatility index and solvency index. EBIT declined 146.23% from -$28.35M to -$69.81M, operating cash flow declined 82.58% from -$21.83M to -$39.87M, and earnings per share declined from -$0.4694 to -$0.7528.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 6/10/2024 due to a decline in the growth index, volatility index and solvency index. EBIT declined 146.23% from -$28.35M to -$69.81M, operating cash flow declined 82.58% from -$21.83M to -$39.87M, and earnings per share declined from -$0.4694 to -$0.7528.
D
Sell
3/25/2024Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 3/25/2024 due to an increase in the volatility index and total return index.
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 3/25/2024 due to an increase in the volatility index and total return index.
E
Sell
3/6/2024Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 3/6/2024 due to a decline in the volatility index.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 3/6/2024 due to a decline in the volatility index.
D
Sell
3/1/2024Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 3/1/2024 due to a major decline in the efficiency index, growth index and solvency index. The quick ratio declined from 31.7 to 18.04, operating cash flow declined 24.12% from -$17.59M to -$21.83M, and net income declined 18.17% from -$33.14M to -$39.16M.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 3/1/2024 due to a major decline in the efficiency index, growth index and solvency index. The quick ratio declined from 31.7 to 18.04, operating cash flow declined 24.12% from -$17.59M to -$21.83M, and net income declined 18.17% from -$33.14M to -$39.16M.
D
Sell
7/27/2023Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 7/27/2023 due to an increase in the volatility index and total return index.
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 7/27/2023 due to an increase in the volatility index and total return index.
D
Sell
7/12/2023Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 7/12/2023 due to a decline in the volatility index.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 7/12/2023 due to a decline in the volatility index.
D
Sell
5/15/2023Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 5/15/2023 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 35 to 50.2.
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 5/15/2023 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 35 to 50.2.
D
Sell
5/3/2023Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 5/3/2023 due to a decline in the volatility index and total return index.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 5/3/2023 due to a decline in the volatility index and total return index.
D
Sell
4/18/2023Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 4/18/2023 due to an increase in the volatility index.
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 4/18/2023 due to an increase in the volatility index.
D
Sell
4/3/2023Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 4/3/2023 due to a decline in the volatility index.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 4/3/2023 due to a decline in the volatility index.
D
Sell
3/17/2023Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 3/17/2023 due to an increase in the volatility index and total return index.
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 3/17/2023 due to an increase in the volatility index and total return index.
D
Sell
3/1/2023Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 3/1/2023 due to a significant decline in the growth index, solvency index and efficiency index. Net income declined 326.87% from -$8.07M to -$34.43M, earnings per share declined from -$0.1 to -$0.4134, and EBIT declined 145.06% from -$16.28M to -$39.9M.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 3/1/2023 due to a significant decline in the growth index, solvency index and efficiency index. Net income declined 326.87% from -$8.07M to -$34.43M, earnings per share declined from -$0.1 to -$0.4134, and EBIT declined 145.06% from -$16.28M to -$39.9M.
D
Sell
8/13/2021Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 8/13/2021 due to a large increase in the growth index, efficiency index and total return index. Total capital increased 1.91% from $586.69M to $597.89M.
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 8/13/2021 due to a large increase in the growth index, efficiency index and total return index. Total capital increased 1.91% from $586.69M to $597.89M.
D
Sell
8/12/2021Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 8/12/2021 due to a major decline in the total return index, volatility index and growth index. Operating cash flow declined 105.29% from $318.52M to -$16.84M, and earnings per share declined from $0.3684 to $0.34.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 8/12/2021 due to a major decline in the total return index, volatility index and growth index. Operating cash flow declined 105.29% from $318.52M to -$16.84M, and earnings per share declined from $0.3684 to $0.34.
D
Sell
4/20/2021Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D from D+ on 4/20/2021 due to a decline in the volatility index and total return index.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D from D+ on 4/20/2021 due to a decline in the volatility index and total return index.
D
Sell
4/5/2021Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D+ from D on 4/5/2021 due to a significant increase in the solvency index, total return index and growth index. Operating cash flow increased 3,459.57% from -$9.48M to $318.52M, EBIT increased 418.01% from -$9.44M to $30.01M, and earnings per share increased from -$1.7431 to $0.3684.
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D+ from D on 4/5/2021 due to a significant increase in the solvency index, total return index and growth index. Operating cash flow increased 3,459.57% from -$9.48M to $318.52M, EBIT increased 418.01% from -$9.44M to $30.01M, and earnings per share increased from -$1.7431 to $0.3684.
D
Sell
1/27/2021None
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D from U on 01/27/2021.
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D from U on 01/27/2021.
NASDAQ
03/13/2025 4:00PM Eastern
Quotes delayed
